I too thought 18% royalty is low also, but based o
Post# of 154125
(Total Views: 200)
Posted On: 04/02/2019 1:50:10 PM
Re: ClosetInvestor #1641
I too thought 18% royalty is low also, but based on what I could find that is in-line with other deals.....so I used it. This likely explains why most of the big pharmas would rather buy they can still make a lot of money with less risk.
What I don't know and maybe someone more knowledgeable in the licensing field can explain is if this percentage increases based on revenue thresholds? Say 18% for first $500M, then 20% between $500M-$1B and 25% anything above $1B?....or what a reasonable rate and threshold limits would be?
This will move the needle a lot more especially as our 10.5% payout rates are likely structured similar but at much small levels sine they were inked much earlier in leronlimab's trial progress.
What I don't know and maybe someone more knowledgeable in the licensing field can explain is if this percentage increases based on revenue thresholds? Say 18% for first $500M, then 20% between $500M-$1B and 25% anything above $1B?....or what a reasonable rate and threshold limits would be?
This will move the needle a lot more especially as our 10.5% payout rates are likely structured similar but at much small levels sine they were inked much earlier in leronlimab's trial progress.
(0)
(0)CytoDyn Inc (CYDY) Stock Research Links
Please do your own due diligence. All my posts and comments are not to be considered investment advice.